Market intelligence for the peptide supply chain
United States ·

US pharmacy groups propose new sourcing rules for six peptide APIs

November 13, 2026 · TideMetrix Brief
TideMetrix TakeUS pharmacy groups want registered domestic intermediaries to verify peptide API suppliers and test product quality before ingredients reach compounding pharmacies. If adopted, the proposal could reshape sourcing channels for six peptides.

Two US pharmacy organizations have proposed new sourcing requirements for six peptide active pharmaceutical ingredients (APIs), potentially giving domestic intermediaries a greater role in supplier qualification and quality assurance.

In a November 13 joint letter to the US Department of Health and Human Services (HHS), the Alliance for Pharmacy Compounding (APC) and National Community Pharmacists Association (NCPA) recommended that compounding pharmacies initially obtain the covered peptides through FDA-registered US repackagers or relabelers.

Under the proposal, these intermediaries would verify the identity and qualifications of original API manufacturers, review supporting documentation and confirm that individual lots meet applicable specifications. Independent US laboratory testing would be required where existing documentation is insufficient.

APC suggested an initial one-year transition period, subject to review. The groups also proposed exceptions for pharmacies able to demonstrate equivalent supplier-qualification and certificate-of-analysis verification capabilities, potentially allowing qualified pharmacies to source directly from manufacturers.

The organizations argue that FDA establishment registration alone does not demonstrate that individual API lots meet quality requirements. They also want clarification on testing obligations and how intermediaries could protect confidential manufacturer information while providing pharmacies with adequate compliance documentation.

The proposal responds to an October HHS policy addressing six peptides: BPC-157, TB-500, epitalon, KPV, MOTS-c and semax.

For peptide API manufacturers and distributors, adoption of the recommendations could introduce additional qualification, documentation and testing requirements for sales into the US compounding market.

The recommendations have not been adopted by HHS or the FDA. The underlying enforcement-discretion framework does not constitute FDA approval of the six substances.

Sources

← Back to News